The objective of each study was to show the superiority of secukinumab over placebo at week @ with respect to the proportion of patients who had a reduction of @ % or more from baseline in the psoriasis area-and-severity index score ( PASI @ ) and a score of @ ( clear ) or @ ( almost clear ) on a @-point modified investigator 's global assessment ( coprimary end points ) .